Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IRIDEXIRIX -10.71%62 Debt-to-Equity is 0.90 as of Mar. 2026, which is 500% above its 10-year median of 0.15. GuruFocus rates IRIX with a GF Score™ of 62/100 and a GF Value™ of $1.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, IRIDEX ranks worse than 82.13% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for IRIDEX's Debt-to-Equity or its related term are showing as below:
IRIX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.15 Max: 6.22
Current: 0.9
During the past 13 years, the highest Debt-to-Equity Ratio of IRIDEX was 6.22. The lowest was 0.09. And the median was 0.15.
IRIX's Debt-to-Equity is ranked worse than 82.13% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs IRIX: 0.90
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
IRIDEX Debt-to-Equity Related Terms
IRIDEX Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for IRIDEX's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRIX vs ICCM, LFWD, GTHP: Debt-to-Equity Comparison
For the Medical Devices subindustry, IRIDEX's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRIDEX Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where IRIDEX's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRIDEX (IRIX) has a Debt-to-Equity of 0.90 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on IRIDEX and its competitors. This is 500% above median its historical median of 0.15. Over the past decade, IRIDEX's Debt-to-Equity has ranged from 0.09 to 6.22. According to the industry distribution chart, IRIDEX ranks #579 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 82.1%.
Is IRIDEX's Debt-to-Equity too high?
IRIDEX's current Debt-to-Equity of 0.90 is 500% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 6.22. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. IRIDEX's value of 0.90 is 291.3% above this industry median. Based on the distribution chart, IRIDEX ranks #579 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, IRIDEX has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRIDEX's Debt-to-Equity compare to ICCM and LFWD?
According to the Medical Devices & Instruments industry distribution chart, IRIDEX ranks #579 out of 705 companies for Debt-to-Equity. This places IRIDEX in the lower half of its industry. The industry median Debt-to-Equity is 0.23. IRIDEX's value of 0.90 is 291.3% above this benchmark. Historically, IRIDEX's own Debt-to-Equity has ranged from 0.09 to 6.22 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.23, IRIDEX has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRIDEX's current Debt-to-Equity of 0.90 is 291.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on IRIDEX and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRIDEX's current Debt-to-Equity is 0.90, which is 500% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRIDEX stock overvalued right now?
Based on GuruFocus' analysis, IRIDEX (IRIX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.70, compared to a current price of $0.94 — trading 44.9% below its estimated fair value. The current Debt-to-Equity is 0.90, which is 500% above median its 10-year median of 0.15 and 291.3% above the Medical Devices & Instruments industry median of 0.23. IRIDEX's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For IRIDEX (IRIX), the current Debt-to-Equity is 0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRIDEX (IRIX) Overvalued in 2026?
Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued.
The current stock price of $0.94 is trading 44.9% below its estimated GF Value™ of $1.70.
GuruFocus considers IRIDEX to be Possible Value Trap.
Key valuation signals for IRIX:
Debt-to-Equity: 0.90 (500% above median its 10-year median of 0.15)
GF Value™: $1.70 vs. price of $0.94 (44.9% below fair value)
Industry Position: 291.3% above the Medical Devices & Instruments median (#579 of 705)
No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
62GF Score
Get the complete analysis for IRIX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRIX has been successfully added to your 
